Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker LLP) - Citizen Petition
This Other document was issued by the Food and Drug Administration (FDA)
For related information, Open Docket Folder
See attached file(s)
No documents available.
Purdue Pharma L P Kleinfeld Kaplan and Becker LLP Citizen Petition
Exhibit 1 Coplan et al National Changes in OxyContin Other Oxycodone and Heroin Exposures Reported to Poison Centers With...
Exhibit 2 Coplan et al Changes After Reformulation of Extended Release Oxycodone in Calls to US Poison Centers for Oxycodone and...
Exhibit 3 Coplan et al Effects of Reformulated OxyContin on Opioid Abuse in the National Poison Data System American Pain...
Exhibit 4 Severtson et al Decline in Rates of Abuse of Extended Release ER Oxycodone Following the Introduction of a Reformulated...
Exhibit 5 Severtson et al Reduced Abuse and Diversion Following the Reformulation of OxyContin RADARS
Exhibit 6 Severtson et al Reduction in OxyContin Diversion Cases Following the Introduction of Reformulated OxyContin
Exhibit 7 Davis et al Reduction in Extended Release Oxycodone Diversion Rates Following The Introduction of A Reformulated ER...
Exhibit 8 Bucher Bartelson et al A Comparison of the Street Price of Original and Reformulated ER Oxycodone
Exhibit 9 Severtson et al A Comparison of the Street Price of Original and Reformulated OxyContin and Immediate Release IR...
Exhibit 10 Chilcoat et al Impact of Reformulated OxyContin on Rates of Abuse Through Oral and non Oral Routes Among Individuals...
Exhibit 11 Cassidy et al Change in Routes of Administration for OxyContin and Comparators Following Introduction of Reformulated...
Exhibit 12 Butler et al Differences in Rates of Abuse and Routes of Administration for Original and Reformulated Extended Release...
Exhibit 13 Black et al Effects of Reformulated OxyContin Among Patients Assessed for Substance Abuse Treatment in the NAVIPPRO...
Exhibit 14 Butler et al Initial Findings on Abuse Rates and Routes of Administration Among Individuals Assessed for Substance use...
Exhibit 15 Cassidy et al Initial findings on abuse rates and routes of administration following introduction of reformulated...
Exhibit 16 De Veaugh Geiss et al Routes of Administration and Frequency of Abuse of OxyContin and Immediate Release Oxycodone in...
Exhibit 17 Leukefeld et al Changes in Prescription and OxyContin Drug Abuse Patterns in a Rural Kentucky County
Exhibit 18 Perrino et al Evaluation of Abuse Potential of Crushed and Intranasally Administered Oxycodone Tablets
Exhibit 19 Colucci et al Safety Tolerability and Pharmacokinetics of Crushed Intranasal Oxycodone Tamper Resistant Tablets and...
Exhibit 20 Harris et al Effects of Various Tampering Methods on Exposure to Oxycodone in Healthy Subjects
Exhibit 21 Sellers et al Relative Attractiveness of Reformulated OxyContin Comparative Assessment of Tampering Potential and...
Exhibit 23 Response to Citizen Petitions and Petitions for Stay of Action Docket No 96P 0459
Exhibit 24 Response to Citizen Petition and Petition for Stay of Action Docket No 93P 0421 Correceted Copy
| || |
Comment Period Closed
Show More Details
Date Posted: Oct 24, 2012
Submitter's Representative: Kleinfeld, Kaplan and Becker LLP
Category: Private Industry - C0003
This document is contained in
Related RINs: None
* This count refers to the total comment/submissions received on this document, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.